SEC Form 4 · accession 0000899243-15-010065
IDERA PHARMACEUTICALS, INC. · IDRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Youssef El Zein
Director · 10% Owner
Pillar Pharmaceuticals I LP
Director · 10% Owner
Pillar Invest Corp
Director · 10% Owner
Pillar Pharmaceuticals II, L.P.
Director · 10% Owner
Pillar Pharmaceuticals III, L.P.
Director · 10% Owner
Pillar Pharmaceuticals IV, L.P.
Director · 10% Owner
Period of report
Dec 15, 2015
Accepted (ET)
Dec 17, 2015 · 6:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000861838
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F4 | Dec 15, 2015 | S$0 | 77,586 | $0.00 | D | 0 | I | See Footnotes |
| Common StockF2,F4 | Dec 15, 2015 | S$0 | 77,586 | $0.00 | D | 0 | I | See Footnotes |
| Common StockF3,F4 | Dec 15, 2015 | S$0 | 77,587 | $0.00 | D | 0 | I | See Footnotes |
| Common StockF5,F4 | Dec 17, 2015 | X | 232,759 | $0.00 | A | 0 | I | See Footnotes |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantsF4,F5 | $0.70 | Dec 17, 2015 | X | 232,759 | D | Nov 9, 2012 | Nov 9, 2017 | Common Stock | 232,759 | 5,034,061 | I |
Explanation of responses
- F1Shares sold by Pillar Pharmaceuticals I, L.P. ("Pillar I"), of which Pillar Invest Corporation ("Pillar GP") is the general partner. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar I and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar I. As of the date hereof, Pillar I owns directly 2,090,126 shares of common stock of the Issuer.
- F2Shares sold by Pillar Pharmaceuticals II, L.P. ("Pillar II"), of which Pillar GP is the general partner. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar II and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar II. As of the date hereof, Pillar II owns directly 6,135,132 shares of common stock of the Issuer.
- F3Shares sold by Pillar Pharmaceuticals III, L.P. ("Pillar III"), of which Pillar GP is the general partner. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar III and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar III. As of the date hereof, Pillar III owns directly 3,871,839 shares of common stock of the Issuer.
- F4Youssef El Zein is a director and controlling stockholder of Pillar GP and serves as the representative of a Pillar I, Pillar II, Pillar III, Pillar IV and Pillar GP on the Issuer's board of directors. Mr. El Zein disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar I, Pillar II, Pillar III and Pillar IV and this report shall not be deemed an admission that he is the beneficial owners of any such securities, except to the extent of his pecuniary interest therein, if any, by virtue of his ownership interest in Pillar GP. As of the date hereof, Mr. El Zein owns directly 496,920 shares of common stock of the Issuer.
- F5Warrants beneficially owned and exercised for shares of common stock by Pillar II. Pillar GP disclaims Section 16 beneficial ownership of the Warrants and the common stock underlying such warrants and this report shall not be deemed an admission that Pillar GP is the beneficial owner of any such securities, except to the extent of its pecuniary interest therein.